Alert detail
LCD L40000: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — CGS
What changed
New LCD impacts billing for myeloproliferative neoplasms testing.
Who’s affected: Hematology billing teams · Effective: August 17, 2025
Affected codes
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 17 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.